Endometriosis-Newer Agents.

 

 

Cabergolin.

Cabergoline in the treatment of endom cabergoline inhibits endometrial VGEF, i think. hence reduces endometrial activity. I think that is how it will act. will do a lit search and get back etriosis..

action mode is down-regulation of VEGF/VEGFR-2, pro-angiogenic cytokines and plasminogen activator inhibitor-1 within the lesions. There have been very few human studies, except from Gomez et al., in humans long term use is known to cause cardiac valvular regurgitation. Most studies are on mice models and extrapolating the data, as to the optimal dose, duration and end-point is not known. For a desperate disease, hypothetical treatment can also be desperate.

Cabergolin 0.5 twice weekly for 12 weeks vs GnRH agonist 3.75 mg monthly for 3 months..The management line was considered to be significantly effective if the endometrioma size was reduced by more than 25 % of its original pretreatment size.

Cabergoline (dostinex) yields better results in decreasing the size of endometrioma, compared to LHRH-agonist by exerting antiangiogenic effects through vascular endothelial growth factor receptor-2 (VEGFR-2) inactivation. It has no major side effects, easier to administer, and cheaper than LHRH agonists.http://www.ncbi.nlm.nih.gov/pubmed/24748338

Does cabergoline help in decreasing endometrioma size compared to L... - PubMed - NCBI

Arch Gynecol Obstet. 2014 Oct;290(4):677-82. doi: 10.1007/s00404-014-3242-4.

http://www.ncbi.nlm.nih.gov/pubmed/25367601

Comparison of efficacy of bromocriptine and cabergoline to GnRH ago... - PubMed - NCBI